Novo Nordisk is committed to reducing its energy consumption, and a major part of the company's future electricity consumption in Denmark will be supplied by wind turbines; the Danish energy company DONG Energy will help Novo Nordisk realize the target. That is the essence of a unique partnership agreement signed today by the two companies.
Under the partnership, which is the first of its kind, Novo Nordisk pledges until 2020 to convert all energy savings realized at its Danish production sites into the purchase of green electricity for its production sites. The energy will be supplied from a new wind farm that DONG Energy is establishing at Horns Rev in Denmark. "With this agreement Novo Nordisk will make a significant contribution towards realizing the Horns Rev II offshore wind farm and will help build the market for renewable energy in Denmark," says Lars Clausen, executive vice president of DONG Energy.
The agreement will contribute significantly to Novo Nordisk's target of reducing its CO2 emissions by 10% below 2004 levels by 2014 - an extremely ambitious target, given the company's projected significant growth in production.
DONG Energy's experts will help identify energy savings options at Novo Nordisk's Danish production sites, which represent 90% of the company's total CO2 emissions. The aim is for all the company's Danish production sites to convert their total consumption of electricity to renewable energy by 2014. "It is important that we all take the CO2 issue seriously and take active steps to deal with it. Therefore this is an extremely important commercial agreement which we hope will serve as an inspiration to many other companies. As an energy company we can contribute significantly towards reducing CO2 emissions - not only through our own efforts to reduce emissions, but also by helping Danish companies realize their visions of taking on added responsibility for our future climate," says Lars Clausen.
It is the hope of DONG Energy that the partnership will become an engine for a higher degree of conversion to renewable energy supplies among other Danish companies. "We are confident that DONG Energy can help us achieve significant energy savings. At the same time, through this partnership agreement, we contribute to generating a financially sustainable basis for wind turbine energy in Denmark," says Lise Kingo, executive vice president and chief of staffs, Novo Nordisk.
Novo Nordisk's CO2 reduction target is the result of an agreement signed with WWF in 2006 as part of the Climate Savers programme. The programme currently comprises 12 global companies that have committed themselves to taking active steps to consume less energy and shift towards renewable energy.
For further information, please contact:
Tel: (+45) 7210 1810
Tel: (+45) 4442 1960
For photos and broadcast-standard video supporting this press release, please visit our Broadcast Room on novonordisk.com - Media
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO'. For more information, visit novonordisk.com.